指南与共识食管胃疾病与幽门螺杆菌消化内镜消化道肿瘤与早癌

美国胃肠病学会临床实践更新:巴雷特食管筛查与监测新技术与创新的专家综述

AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2022-07-03

美国胃肠病学会临床实践更新委员会发布关于巴雷特食管筛查与监测进展的专家综述,提出15条最佳实践建议,涵盖标准内镜筛查、非内镜细胞收集、高清白光与虚拟色素内镜、Prague分型、先进影像辅助、西雅图活检方案、宽区域经上皮取样、组织系统病理预测、风险分层模型、专家病理复核、转诊至专家内镜医师、质子泵抑制剂治疗及监测间隔等。

要点

  • 具有至少3项巴雷特食管或食管腺癌危险因素者,可考虑标准上消化道内镜筛查。
  • 筛查与监测内镜应采用高清白光内镜和虚拟色素内镜,并按西雅图活检方案取样。
  • 非不典型增生巴雷特食管患者应每3至5年接受监测内镜。

核心结论

  • 本专家综述提供关于巴雷特食管筛查与监测新技术与创新的最佳实践建议,未对证据质量或推荐强度进行正式评级。

研究设计与样本

  • 由美国胃肠病学会临床实践更新委员会委托并批准的专家综述,基于现有文献的专家审阅结合讨论与专家意见制定,经内部同行评议和《临床胃肠病学与肝病学》标准程序外部同行评议。

主要发现

  • 最佳实践建议1:具有至少3项已确立的巴雷特食管和食管腺癌危险因素(包括男性、非西班牙裔白人、年龄>50岁、吸烟史、慢性胃食管反流病、肥胖或巴雷特食管/食管腺癌家族史)的个体,可考虑标准上消化道内镜筛查。
  • 最佳实践建议2:非内镜细胞收集装置可作为筛查巴雷特食管的一种选择考虑。
  • 最佳实践建议3:筛查和监测内镜检查应使用高清白光内镜和虚拟色素内镜,内镜医师应花费足够时间检查巴雷特食管段。
  • 最佳实践建议4:筛查和监测检查应使用标准化分级系统(布拉格分型)记录柱状上皮化生食管的周径和最大范围,并清晰描述标志物及可见病变(结节、溃疡)的位置和特征(如存在)。
  • 最佳实践建议6:筛查和监测检查中的取样应采用西雅图活检方案(每1-2厘米四象限活检,并对任何可见病变进行靶向活检)。

关键数值与推荐

  • 最佳实践建议5:内镜显微镜等先进影像技术可作为辅助技术用于识别不典型增生。
  • 最佳实践建议7:宽区域经上皮取样可作为辅助技术用于取样可疑或已确立的巴雷特食管段(在西雅图活检方案基础上)。
  • 最佳实践建议8:存在不典型增生或恶性肿瘤担忧的糜烂性食管炎患者应进行活检,并在每日两次质子泵抑制剂治疗8周后重复内镜检查。
  • 最佳实践建议9:基于组织系统病理学的预测检测可用于非不典型增生巴雷特食管患者的风险分层。
  • 最佳实践建议14:非不典型增生巴雷特食管患者应每3至5年接受监测内镜。

临床怎么用

  • 最佳实践建议10:风险分层模型可用于选择性识别巴雷特食管相关肿瘤风险个体。
  • 最佳实践建议11:鉴于病理学家之间存在显著的观察者间变异,巴雷特食管相关肿瘤的诊断应由专家病理复核确认。
  • 最佳实践建议12:巴雷特食管相关肿瘤患者应转诊至在先进影像、切除和消融方面具有专长的内镜医师。
  • 最佳实践建议13:所有巴雷特食管患者应至少每日接受质子泵抑制剂治疗。
  • 最佳实践建议15:内镜根除治疗后监测的患者,无论原巴雷特食管段长度如何,均应对食管胃交界处、胃贲门和新鳞状上皮远端2厘米以及所有可见病变进行随机活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this best practice advice (BPA) article from the Clinical Practice Update Committee of the American Gastroenterological Association is to provide an update on advances and innovation regarding the screening and surveillance of Barrett's esophagus. METHODS: The BPA statements presented here were developed from expert review of existing literature combined with discussion and expert opinion to provide practical advice. Formal rating of the quality of evidence or strength of BPAs was not the intent of this clinical practice update. This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. BEST PRACTICE ADVICE 1: Screening with standard upper endoscopy may be considered in individuals with at least 3 established risk factors for Barrett's esophagus (BE) and esophageal adenocarcinoma, including individuals who are male, non-Hispanic white, age >50 years, have a history of smoking, chronic gastroesophageal reflux disease, obesity, or a family history of BE or esophageal adenocarcinoma. BEST PRACTICE ADVICE 2: Nonendoscopic cell-collection devices may be considered as an option to screen for BE. BEST PRACTICE ADVICE 3: Screening and surveillance endoscopic examination should be performed using high-definition white light endoscopy and virtual chromoendoscopy, with endoscopists spending adequate time inspecting the Barrett's segment. BEST PRACTICE ADVICE 4: Screening and surveillance exams should define the extent of BE using a standardized grading system documenting the circumferential and maximal extent of the columnar lined esophagus (Prague classification) with a clear description of landmarks and the location and characteristics of visible lesions (nodularity, ulceration), when present. BEST PRACTICE ADVICE 5: Advanced imaging technologies such as endomicroscopy may be used as adjunctive techniques to identify dysplasia. BEST PRACTICE ADVICE 6: Sampling during screening and surveillance exams should be performed using the Seattle biopsy protocol (4-quadrant biopsies every 1-2 cm and target biopsies from any visible lesion). BEST PRACTICE ADVICE 7: Wide-area transepithelial sampling may be used as an adjunctive technique to sample the suspected or established Barrett's segment (in addition to the Seattle biopsy protocol). BEST PRACTICE ADVICE 8: Patients with erosive esophagitis should be biopsied when concern of dysplasia or malignancy exists. A repeat endoscopy should be performed after 8 weeks of twice a day proton pump inhibitor therapy. BEST PRACTICE ADVICE 9: Tissue systems pathology-based prediction assay may be utilized for risk stratification of patients with nondysplastic BE. BEST PRACTICE ADVICE 10: Risk stratification models may be utilized to selectively identify individuals at risk for Barrett's associated neoplasia. BEST PRACTICE ADVICE 11: Given the significant interobserver variability among pathologists, the diagnosis of BE-related neoplasia should be confirmed by an expert pathology review. BEST PRACTICE ADVICE 12: Patients with BE-related neoplasia should be referred to endoscopists with expertise in advanced imaging, resection, and ablation. BEST PRACTICE ADVICE 13: All patients with BE should be placed on at least daily proton pump inhibitor therapy. BEST PRACTICE ADVICE 14: Patients with nondysplastic BE should undergo surveillance endoscopy in 3 to 5 years. BEST PRACTICE ADVICE 15: In patients undergoing surveillance after endoscopic eradication therapy, random biopsies should be taken of the esophagogastric junction, gastric cardia, and the distal 2 cm of the neosquamous epithelium as well as from all visible lesions, independent of the length of the original BE segment.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Muthusamy VR, Wani S, Gyawali CP, et al. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review. Clin Gastroenterol Hepatol. 2022. PMID: 35788412. doi:10.1016/j.cgh.2022.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。